Crystal of substituted piperazine derivative and preparation method therefor
Patent Information
- Application Number
- MYPI2025002842
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-14
- Filing Date
- 2023-11-14
- Publication Date
- 2024-05-14
Smart Images

Figure PI2025002842_DRAWING_001 
Figure PI2025002842_DRAWING_002 
Figure PI2025002842_DRAWING_003
Abstract
Description
A crystal of a substituted piperazine derivative and a preparation method thereof Technical Field
[0001] The present invention relates to a substituted piperazine derivative crystal and a preparation method thereof. Specifically, the present invention provides crystal forms A to I of the compound represented by formula ① and a preparation method thereof. Background Art
[0002] ADP-ribosylation (ADP-ribosylation) is a post-transcriptional protein modification process in which single or multiple adenosine diphosphate ribose (ADP-ribose) groups are incorporated into amino acid residues in proteins. ADP-ribosylation is a reversible process involved in physiological regulation, including cell signaling, DNA damage repair, transcription, gene expression regulation, and apoptosis. ADP-ribose is derived from the redox cofactor nicotinamide adenine dinucleotide (NAD+), and the enzymes that mediate this ADP-ribose incorporation modification are ADP-ribosylases. In regulating this physiological response, the N-glycosidic bond connecting the ADP-ribose molecule to the nicotinamide group of NAD+ is cleaved, allowing the molecule to form a bond with the corresponding amino acid residue in the target protein. ADP-ribosylases can perform two types of modification: mono-ADP-ribosylation and poly-ADP-ribosylation. When DNA is damaged or cells are subjected to stress, PARP is activated, resulting in an increase in poly (ADP-ribose) and a decrease in NAD+. For over a decade, PARP1 was believed to be the only poly (ADP-ribose) polymerase in mammalian cells, and therefore the enzyme has been the most studied. To date, scientists have identified 17 different PARPs. MonoPARPs occupy the majority of the PARP family and mediate important biological functions and various stress responses, such as the unfolded protein response, NF-κB signaling, antiviral responses, and cytokine signaling. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly (ADP-ribose) polymerase (PARP-7) is a member of the MonoPARP family, and its expression is regulated by the TCDD-activated aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor that mediates the toxic activity of many environmental xenobiotics. AHR upregulates PARP-7 expression. PARP-7 interacts with the kinase TBK1 and causes its ADP-ribosylation, inhibiting TBK1 activity and downregulating IFN-I (type I interferon) responses, thereby suppressing the body's antiviral and tumor immune responses. To date, no clinical results have been reported for PARP7 inhibitors, making their research of interest of great significance.
[0003] PCT / CN2022 / 094124 provides a piperazine derivative, whose chemical name is (S)-4-(trifluoromethyl)-5-((1-((5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)pyridazin-3(2H)-one, providing patients with a new treatment option.
[0004] The crystal structure of a pharmaceutically active ingredient often affects the chemical and physical stability of the drug. Variations in crystal form, preparation method, and storage conditions can lead to variations in the compound's crystal structure, sometimes resulting in the formation of alternative morphologies. Generally, amorphous pharmaceutical products lack a regular crystal structure and often exhibit other defects, such as poor product stability, difficulty in filtration, caking, and poor flowability. Given the importance of solid drug crystal forms and their stability in clinical treatment, in-depth research on the crystal form of the compound (S)-4-(trifluoromethyl)-5-((1-((5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)pyridazin-3(2H)-one is of great significance for the development of pharmaceuticals suitable for industrial production and exhibiting excellent biological activity.
[0005] Summary of the Invention
[0006] The present invention provides a crystal of (S)-4-(trifluoromethyl)-5-((1-((5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)pyridazin-3(2H)-one (Compound ①). Compound ① has the following chemical structure:
[0007] The crystals of the present invention exhibit at least one of the following advantages: good solubility, high stability, easy handling, processing, and purification, improved oral bioavailability of drugs, extended drug storage period, and ease of manufacture in various dosage forms.
[0008] The crystals of the present invention exhibit pharmaceutical advantages over the amorphous form of compound ①. In particular, the crystals have enhanced chemical and physical stability, making them more suitable for preparing solid pharmaceutical dosage forms containing pharmacologically active ingredients.
[0009] The crystalline form of the present invention is present in an amount of about 5% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 10% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 15% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 20% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 25% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 30% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 35% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 40% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 45% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 50% to about 100% by weight of the drug substance.
[0010] In certain embodiments, the crystalline form of the present invention is present in an amount of about 55% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 60% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 65% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 70% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 75% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 80% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 85% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 90% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 95% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the present invention is present in an amount of about 98% to about 100% by weight of the drug substance. In certain embodiments, the crystalline form of the invention is present in about 99% to about 100% by weight of the drug substance. In certain embodiments, substantially all of the drug substance is a crystalline form of the invention, i.e., the drug substance is substantially phase-pure crystals.
[0011] Unless otherwise specified, compound ① of the present invention is the amorphous form of compound ①.
[0012] One embodiment of the crystal of the present invention is crystal form A of compound ①, characterized in that the X-ray powder diffraction pattern of crystal form A has characteristic diffraction peaks at the following 2θ positions: 10.389°±0.3°, 11.917°±0.3°, 12.912°±0.3°, 13.385°±0.3°, 14.054°±0.3°, 15.316°±0.3°, and 16.636°±0.3°.
[0013] Furthermore, the X-ray powder diffraction pattern of crystal form A has characteristic diffraction peaks at the following 2θ positions: 6.716°±0.3°, 10.043°±0.3°, 10.389°±0.3°, 11.917°±0.3°, 12.912°±0.3°, 13.385°±0.3°, 14.054°±0.3°, 15.316°±0.3°, 16.636°±0.3°, 18.003°±0.3°, 20.014°±0.3°, 20.794°±0.3°, and 23.855°±0.3°.
[0014] Furthermore, the X-ray powder diffraction pattern of Form A is basically as shown in FIG1 .
[0015] The TGA curve of the crystal form A described in the present invention is basically as shown in Figure 10.
[0016] The DSC curve of the crystal form A described in the present invention is basically shown in Figure 11.
[0017] The present invention also relates to a method for preparing crystal form A, characterized in that the compound represented by formula ① is crystallized in a solvent (①-A) to obtain crystal form A; the solvent (①-A) is selected from any one of acetonitrile, ethanol, n-propanol, acetone and water, or a mixed solvent of any several of them in any proportion.
[0018] Furthermore, the preparation method of crystal form A is characterized in that the compound represented by formula ① or its crude product is added to a solvent (①-A-1), heated to dissolve, then solvent (①-A-2) and solvent (①-A-3) are added, heated to dissolve, cooled and continued to stir, and allowed to stand for crystallization to obtain crystal form A; the solvent (①-A-1), solvent (①-A-2), and solvent (①-A-3) are selected from any one of acetonitrile, ethanol, n-propanol, acetone and water.
[0019] One embodiment of the crystal of the present invention is form B of compound ①, characterized in that the X-ray powder diffraction pattern of form B has characteristic diffraction peaks at the following 2θ positions: 6.498°±0.3°, 13.326°±0.3°, 21.229°±0.3°, 21.426°±0.3°, and 22.195°±0.3°.
[0020] Furthermore, the X-ray powder diffraction pattern of form B has characteristic diffraction peaks at the following 2θ positions: 6.498°±0.3°, 9.657°±0.3°, 11.420°±0.3°, 13.027°±0.3°, 13.326°±0.3°, 15.882°±0.3°, 19.075°±0.3°, 19.315°±0.3°, 20.669°±0.3°, 21.229°±0.3°, 21.426°±0.3°, 22.195°±0.3°, 23.118°±0.3°, and 23.362°±0.3°.
[0021] Furthermore, the X-ray powder diffraction pattern of Form B is basically as shown in FIG2 .
[0022] The present invention also relates to a method for preparing crystal form B, which is characterized in that the compound represented by formula ① is slurried in a solvent (①-B) to obtain crystal form B; the solvent (①-B) is selected from n-hexane.
[0023] One embodiment of the crystal of the present invention is Form C of compound ①, characterized in that the X-ray powder diffraction pattern of Form C has characteristic diffraction peaks at the following 2θ positions: 19.066°±0.3°, 20.300°±0.3°, 20.978°±0.3°, and 21.616°±0.3°.
[0024] Furthermore, the X-ray powder diffraction pattern of form C has characteristic diffraction peaks at the following 2θ positions: 6.790°±0.3°, 9.917°±0.3°, 11.533°±0.3°, 12.600°±0.3°, 13.556°±0.3°, 13.793°±0.3°, 14.275°±0.3°, 15.008°±0.3°, 16.452°±0.3°, 17.877°±0.3°, 19.066°±0.3°, 19.774°±0.3°, 20.300°±0.3°, 20.978°±0.3°, 21.616°±0.3°, 22.585°±0.3°, and 23.407°±0.3°.
[0025] Furthermore, the X-ray powder diffraction pattern of Form C is basically as shown in FIG3 .
[0026] The present invention also relates to a method for preparing crystal form C, which is characterized in that the compound represented by formula ① is crystallized in a solvent (①-C) to obtain crystal form C; the solvent (①-C) is selected from isopropyl acetate, n-hexane or a mixed solvent of isopropyl acetate and n-hexane.
[0027] One embodiment of the crystal of the present invention is the D form of compound ①, characterized in that the D form has characteristic diffraction peaks at the following 2θ positions in its X-ray powder diffraction pattern: 6.646°±0.3°, 13.175°±0.3°.
[0028] Furthermore, the X-ray powder diffraction pattern of form D has characteristic diffraction peaks at the following 2θ positions: 6.646°±0.3°, 13.175°±0.3°, 13.489°±0.3°, 16.450°±0.3°, 20.950°±0.3°, 21.585°±0.3°, 22.369°±0.3°, 23.036°±0.3°, and 23.281°±0.3°.
[0029] Furthermore, the X-ray powder diffraction pattern of Form D is basically as shown in FIG4 .
[0030] The present invention also relates to a method for preparing crystal form D, which is characterized in that the compound represented by formula ① is extracted with a solvent (①-D), concentrated and vacuum-dried to obtain crystal form D; the solvent (①-D) is selected from ethyl acetate.
[0031] One embodiment of the crystal of the present invention is the E crystal form of compound ①, characterized in that the E crystal form has characteristic diffraction peaks at the following 2θ positions in its X-ray powder diffraction pattern: 18.227°±0.3°, 19.954°±0.3°, and 22.449°±0.3°.
[0032] Furthermore, the X-ray powder diffraction pattern of Form E has characteristic diffraction peaks at the following 2θ positions: 8.129°±0.3°, 11.118°±0.3°, 11.360°±0.3°, 11.749°±0.3°, 13.482°±0.3°, 14.730°±0.3°, 18.227°±0.3°, 19.954°±0.3°. 3°, 20.712°±0.3°, 21.092°±0.3°, 22.449°±0.3°, 22.813°±0.3°, 24.399°±0.3°, 24.560°±0.3°, 25.923°±0.3°, 26.429°±0.3°, 27.060°±0.3°, 27.446°±0.3°.
[0033] Furthermore, the X-ray powder diffraction pattern of Form E is basically as shown in FIG5 .
[0034] The present invention also relates to a method for preparing Form E, characterized in that the compound represented by Formula ① is crystallized in a solvent (①-E) to obtain Form E; the solvent (①-E) is selected from ethyl acetate, n-hexane, or a mixed solvent of ethyl acetate and n-hexane. One embodiment of the crystals of the present invention is Form F of Compound ①, characterized in that Form F has characteristic diffraction peaks at the following 2θ positions: 6.717°±0.3° and 13.484°±0.3° in its X-ray powder diffraction pattern.
[0035] Furthermore, the X-ray powder diffraction pattern of form F has characteristic diffraction peaks at the following 2θ positions: 6.717°±0.3°, 9.812°±0.3°, 11.426°±0.3°, 12.501°±0.3°, 13.484°±0.3°, 14.915°±0.3°, 16.374°±0.3°, 16.884°±0.3°, 17.828°±0.3°, 18.975°±0.3°, 20.241°±0.3°, 20.902°±0.3°, 21.593°±0.3°, 22.506°±0.3°, 22.918°±0.3°, and 23.412°±0.3°.
[0036] Furthermore, the X-ray powder diffraction pattern of Form F is basically as shown in FIG6 .
[0037] The TGA curve of the F crystal form described in the present invention is basically as shown in Figure 12.
[0038] The DSC curve of the F crystal form described in the present invention is basically as shown in Figure 13.
[0039] The present invention also relates to a method for preparing the F crystal form, which is characterized in that the compound represented by formula ① is crystallized in a solvent (①-F) to obtain the F crystal form; the solvent (①-F) is selected from n-propanol, n-heptane or a mixed solvent of n-propanol and n-heptane.
[0040] One embodiment of the crystal of the present invention is the G crystal form of compound ①, characterized in that the G crystal form has characteristic diffraction peaks at the following 2θ positions in its X-ray powder diffraction pattern: 6.743°±0.3°, 13.503°±0.3°.
[0041] Furthermore, the X-ray powder diffraction pattern of Form G has characteristic diffraction peaks at the following 2θ positions: 6.743°±0.3°, 13.503°±0.3°, 16.901°±0.3°, 18.996°±0.3°, 20.260°±0.3°, 20.920°±0.3°, and 21.604°±0.3°. Furthermore, the X-ray powder diffraction pattern of Form G is substantially as shown in Figure 7.
[0042] The present invention also relates to a method for preparing the G crystal form, which is characterized in that the compound represented by formula ① is crystallized in a solvent (①-G) to obtain the G crystal form; the solvent (①-G) is selected from ethanol, n-heptane or a mixed solvent of ethanol and n-heptane.
[0043] One embodiment of the crystal of the present invention is the H crystal form of compound ①, characterized in that the H crystal form has an X-ray powder diffraction pattern having characteristic diffraction peaks at the following 2θ positions: 12.366°±0.3°, 13.115°±0.3°, 14.359°±0.3°, 15.617°±0.3°, and 16.909°±0.3°.
[0044] Furthermore, the X-ray powder diffraction pattern of the H crystal form has characteristic diffraction peaks at the following 2θ positions: 6.514°±0.3°, 10.074°±0.3°, 10.684°±0.3°, 12.366°±0.3°, 13.115°±0.3°, 14.359°±0.3°, 15.617°±0.3°, 16.909°±0.3°, 19.839°±0.3°, 20.092°±0.3°, 20.687°±0.3°, and 22.919°±0.3°.
[0045] Furthermore, the X-ray powder diffraction pattern of the H crystal form is basically shown in Figure 8.
[0046] The TGA curve of the H crystal form described in the present invention is basically as shown in Figure 14.
[0047] The DSC curve of the H crystal form described in the present invention is basically as shown in Figure 15.
[0048] The present invention also relates to a method for preparing the H crystal form, which is characterized in that the compound represented by formula ① is crystallized in a solvent (①-H) to obtain the H crystal form; the solvent (①-H) is selected from any one of acetonitrile, ethanol, n-propanol, acetone and water, or a mixed solvent of any several of them in any proportion.
[0049] One embodiment of the crystal of the present invention is Form I of compound ①, characterized in that the X-ray powder diffraction pattern of Form I has characteristic diffraction peaks at the following 2θ positions: 4.968°±0.3°, 19.770°±0.3°, and 21.752°±0.3°.
[0050] Furthermore, the X-ray powder diffraction pattern of Form I has characteristic diffraction peaks at the following 2θ positions: 4.968°±0.3°, 8.863°±0.3°, 12.739°±0.3°, 13.896°±0.3°, 14.848°±0.3°, 18.840°±0.3°, 19.179°±0.3°, 19.770°±0.3°, 21.155°±0.3°, 21.752°±0.3°, and 24.053°±0.3°.
[0051] Furthermore, the X-ray powder diffraction pattern of Form I is basically as shown in Figure 8.
[0052] The present invention also relates to a method for preparing crystal form I, characterized in that the compound represented by formula ① is crystallized in a solvent (①-I) to obtain crystal form I; the solvent (①-I) is selected from acetonitrile, water, or a mixed solvent of acetonitrile and water.
[0053] The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of the crystalline compound of the present invention and one or more pharmaceutically acceptable carriers or excipients.
[0054] The crystal of the present invention can be used as an active pharmaceutical ingredient, or a pharmaceutical composition containing the crystal as an active ingredient, in drugs for treating and / or preventing cancer.
[0055] In one or more embodiments, there is provided use of the crystal of the present invention as an active pharmaceutical ingredient, or a pharmaceutical composition containing the crystal as an active ingredient, in the preparation of a drug for treating and / or preventing solid tumors.
[0056] In one or more embodiments, the solid tumor of the present invention is selected from non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, hormone receptor-positive (HR+) breast cancer, colon cancer or PARP7 amplified advanced solid tumor.
[0057] The X-ray powder diffraction pattern disclosed in the present invention and those substantially the same also fall within the scope of the present invention.
[0058] It is understood that, as is well known in the art of differential scanning calorimetry (DSC), the height of the melting peak of a DSC curve depends on many factors related to sample preparation and instrument geometry, while the peak position is relatively insensitive to experimental details. Therefore, in some embodiments, the crystalline compound of the present invention is characterized by a DSC pattern having characteristic peak positions, having substantially the same properties as the DSC pattern provided in the accompanying drawings of the present invention, with an error tolerance of ±3°C.
[0059] Unless stated otherwise, the terms used in the specification and claims have the following meanings.
[0060] An "effective amount" refers to that amount of a compound that will elicit the physiological or medical translation in the tissue, system, or subject being treated, and includes an amount of the compound that, when administered to a subject, is sufficient to prevent or alleviate to some extent one or more symptoms of the disorder or condition being treated.
[0061] “IC 50 ” refers to the half-maximal inhibitory concentration, which is the concentration at which half of the maximum inhibitory effect is achieved.
[0062] The crystal structures of the present invention can be analyzed using various analytical techniques known to those of ordinary skill in the art, including, but not limited to, X-ray powder diffraction (XRD).
[0063] It is understood that the numerical values described and protected by the present invention are approximate values. Variations in the numerical values may be due to equipment calibration, equipment errors, crystal purity, crystal size, sample size and other factors.
[0064] It is understood that the crystals of the present invention are not limited to characteristic spectra that are exactly the same as the characteristic spectra described in the drawings disclosed in the present invention, such as XRD. Any crystal form having characteristic spectra that are substantially the same or essentially the same as those described in the drawings falls within the scope of the present invention.
[0065] Various modifications and alterations to the present invention will become apparent to those skilled in the art from consideration of the specification and practice of the invention without departing from the scope and spirit of the invention.
[0066] Unless otherwise stated, the English abbreviations used in the specification and claims have the following meanings. BRIEF DESCRIPTION OF THE DRAWINGS
[0067] FIG1 is an X-ray powder diffraction pattern of Form A.
[0068] FIG2 is an X-ray powder diffraction pattern of Form B.
[0069] FIG3 is an X-ray powder diffraction pattern of Form C.
[0070] FIG4 is an X-ray powder diffraction pattern of Form D.
[0071] FIG5 is an X-ray powder diffraction pattern of Form E.
[0072] FIG6 is an X-ray powder diffraction pattern of Form F.
[0073] FIG7 is an X-ray powder diffraction pattern of Form G.
[0074] FIG8 is an X-ray powder diffraction pattern of Form H.
[0075] FIG9 is an X-ray powder diffraction pattern of Form I.
[0076] FIG10 is a TGA diagram of Form A.
[0077] FIG11 is a DSC diagram of Form A.
[0078] FIG12 is a TGA chart of Form F.
[0079] FIG13 is a DSC graph of Form F.
[0080] FIG14 is a TGA chart of Form H.
[0081] FIG15 is a DSC chart of Form H. DETAILED DESCRIPTION
[0082] The following describes in detail the implementation process of the present invention and the beneficial effects produced by specific embodiments, which is intended to help readers better understand the essence and characteristics of the present invention and is not intended to limit the scope of implementation of this case.
[0083] Unless otherwise specified in the examples, the solution refers to an aqueous solution.
[0084] Unless otherwise specified, the experimental conditions for crystallization are generally room temperature (20-30° C., 30-70% RH), and the solvent ratio refers to the volume ratio.
[0085] Intermediate 1
[0086] 5-Chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (Intermediate 1)
[0087] 5-chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one
[0088] first step:
[0089] 4,5-Dibromo-2-(4-methoxybenzyl)pyridazin-3(2H)-one (1b)
[0090] 4,5-dibromo-2-(4-methoxybenzyl)pyridazin-3(2H)-one
[0091] To a solution of 4,5-dibromo-2,3-dihydropyridazin-3-one (1a, 50 g, 196.94 mmol, 1.0 equiv) in N,N-dimethylformamide (500 mL) was added portionwise sodium hydride (11.82 g, 295.41 mmol, 1.5 equiv, 60%) at 0-10°C. This was followed by the addition of 1-(chloromethyl)-4-methoxybenzene (46.06 g, 294.11 mmol, 1.49 equiv) at 0°C. After the addition, the reaction mixture was stirred at room temperature for 3 h. Upon completion, the reaction mixture was slowly poured into 1.0 L of ice-water mixture to quench the reaction and extracted with dichloromethane (2 x 500 mL). The organic layers were combined and concentrated. The solid was washed with methanol (500 mL x 2) to afford 1b as a yellow solid (48.4 g, 66% yield).
[0092] LC-MS m / z(ESI)=375.00[M+1].
[0093] Step 2:
[0094] 4-Bromo-5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one (1c)
[0095] 4-bromo-5-methoxy-2-(4-methoxybenzyl)pyridazin-3(2H)-one
[0096] 1b (48.4 g, 129.40 mmol, 1.0 equiv) and potassium hydroxide (21.78 g, 388.30 mmol, 3.00 equiv) were dissolved in methanol (417 mL) and stirred at room temperature for 2 h. The resulting reaction mixture was concentrated to 80 mL and filtered to obtain the crude product. The resulting filter cake was slurried in water (160 mL) for 1 h and filtered to obtain 1c as a white solid (38.72 g, 92% yield). LC-MS m / z (ESI) = 326.30 [M+1].
[0097] Step 3:
[0098] 5-Methoxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (1d)
[0099] 5-methoxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one
[0100] 1c (14 g, 43.04 mmol, 1.0 equiv) and CuI (4.10 g, 21.52 mmol, 0.50 equiv) were weighed into a 250 mL reaction flask and dissolved in N-methylpyrrolidone (72 mL). Methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (16.4 mL, 129.11 mmol, 3.0 equiv) was then slowly added. After the addition, the reaction was stirred in an oil bath at 100°C for 3 h. Upon completion, the reaction mixture was quenched by the addition of 90 mL of water. The resulting solution was extracted with dichloromethane (3 × 60 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether:ethyl acetate = 1:1) to afford 1d as a white solid (12.1 g, 89% yield).
[0101] LC-MS m / z(ESI)=315.10[M+1].
[0102] Step 4:
[0103] 5-Hydroxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (1e)
[0104] 5-hydroxy-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one
[0105] To a solution of 1d (12.1 g, 38.52 mmol, 1.0 equiv) in N,N-dimethylformamide (60 mL) was added dropwise trimethylsilyl iodide (9.97 g, 50.07 mmol, 1.3 equiv) at room temperature. The resulting reaction mixture was stirred at 85°C for 20 h. Upon completion, the reaction mixture was quenched by the addition of 60 mL of water, and the resulting solution was extracted with dichloromethane (3 x 60 mL). The combined organic phases were dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by column chromatography (petroleum ether:ethyl acetate = 1:1) to afford 1e as a white solid (10.4 g, 90% yield).
[0106] LC-MS m / z(ESI)=301.07[M+1].
[0107] Step 5:
[0108] 5-Chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one (Intermediate 1)
[0109] 5-chloro-2-(4-methoxybenzyl)-4-(trifluoromethyl)pyridazin-3(2H)-one
[0110] To a solution of compound 1e (10.4 g, 34.66 mmol, 1.0 equiv) in N,N-dimethylformamide (52 mL) was slowly added dropwise oxalyl chloride (8.79 g, 69.32 mmol, 2.0 equiv) at 0°C. The reaction mixture was stirred at room temperature for 8 h. Upon completion of the reaction, 550 mL of water was added to quench the reaction mixture. The mixture was filtered to afford Intermediate 1 as a white solid (11.04 g, 99%).
[0111] LC-MS m / z(ESI)=319.68[M+1].
[0112] Intermediate 2
[0113] (S)-1-((5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-amine (Intermediate 2)
[0114] (S)-1-((5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-amine
[0115] first step:
[0116] Ethyl 5-(4-methoxybenzyl)-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate (2b)
[0117] Ethyl-5-(4-methoxybenzyl)-4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate: 4-Oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxylate (2a, 5.0 g, 24 mmol, 1.0 equiv) and p-methoxybenzyl bromide (4.2 mL, 28.8 mmol, 1.2 equiv) were dissolved in N,N-dimethylformamide (50 mL). Sodium hydride (1.15 g, 28.8 mmol, 1.2 equiv) was slowly added under ice-cooling. The mixture was allowed to react at room temperature for 3 h. After completion of the reaction, the mixture was quenched with water, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the organic phase was evaporated to dryness. The crude product was purified by flash column chromatography (dichloromethane:methanol=20:1) to give 2b as a white solid (7.5 g, 92% yield).
[0118] 1 H NMR (400MHz, DMSO-d6): δ7.33–7.23(m,2H),7.14(s,1H),6.94–6.87(m,2H), 4.62(s,2H),4.50–4.38(m,2H),4.28(q,2H),3.76–3.69(m,5H),1.29(t,3H).
[0119] LC-MS m / z(ESI)=330.10[M+1].
[0120] Step 2:
[0121] (5-(4-Methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methanol (2c)
[0122] (5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methanol
[0123] 2b (4.1 g, 12.5 mmol, 1.0 equiv) was dissolved in tetrahydrofuran (100 mL). Under nitrogen, a solution of lithium aluminum tetrahydride in tetrahydrofuran (50 mL, 50 mmol, 4.0 equiv) was slowly added dropwise in an ice bath. The temperature was raised to 70°C and the reaction mixture was allowed to react for 10 min. Upon completion of the reaction, the mixture was cooled to room temperature and quenched in an ice-water bath. The filtrate was filtered and dried. The crude product was purified by flash column chromatography (dichloromethane:methanol = 10:1) to afford 2c as a yellow solid (2.45 g, 71% yield).
[0124] LC-MS m / z(ESI)=274.10[M+1].
[0125] Step 3:
[0126] (S)-1-((5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-amine (Intermediate 2)
[0127] (S)-1-((5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-amine
[0128] To a 25 mL reaction vial, 2c (864 mg, 3.16 mmol, 1.0 equiv) was added and dissolved in anhydrous N,N-dimethylformamide (18 mL). Under nitrogen protection, sodium hydride (300 mg, 7.51 mmol, 2.5 eq) was added portionwise at 0°C. After addition, stirring was continued at this temperature for 30 min. Subsequently, a solution of (S)-tert-butyl 4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide in N,N-dimethylformamide (18 mL) was slowly added dropwise to the reaction system, maintaining the temperature at 0°C and stirring for 2 h. Upon completion of the reaction, the pH of the reaction system was adjusted to 3 and stirred at room temperature for 0.5 h. The reaction mixture was extracted with EA (3 x 120 mL). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain a crude product, which was purified by column chromatography (dichloromethane:methanol=40:1) to give intermediate 2 as a white solid (252 mg, 24% yield).
[0129] LC-MS m / z(ESI)=331.50[M+1].
[0130] Intermediate 3
[0131] (S)-5-((1-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (Intermediate 3)
[0132] (S)-5-((1-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one
[0133] first step:
[0134] (S)-2-(4-methoxybenzyl)-5-((1-((5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (3a)
[0135] (S)-2-(4-methoxybenzyl)-5-((1-((5-(4-methoxybenzyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one
[0136] Intermediate 2 (252 mg, 0.764 mmol, 1.0 eq) and intermediate 1 (291.4 mg, 0.916 mmol, 1.1 equiv) were weighed into a 10 mL reaction vial and dissolved in N,N-dimethylformamide (3.0 mL). Subsequently, N,N-diisopropylethylamine (0.5 mL, 3.06 mmol, 4.0 equiv) was added. The mixture was stirred at 100°C for 4 h. After completion of the reaction, the mixture was concentrated in vacuo, and the residue was purified by column chromatography (petroleum ether:ethyl acetate = 1:1.5) to afford 3a as a white solid (359.8 mg, 77% yield).
[0137] LC-MS m / z(ESI)=613.62[M+1].
[0138] Step 2:
[0139] (S)-5-((1-(((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one (Intermediate 3)
[0140] (S)-5-((1-((4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)-4-(trifluoromethyl)pyridazin-3(2H)-one
[0141] To a 10 mL reaction flask containing 3a (359.8 mg, 0.588 mmol, 1.0 equiv) was added trifluoroacetic acid (3.4 mL) and trifluoromethanesulfonic acid (0.42 mL, 4.7 mmol, 8.0 equiv) sequentially. After addition, the reaction was stirred at 25°C for 1 h. The reaction was then stirred in a 70°C oil bath. Upon completion, the reaction was quenched by the addition of 15 mL of water. The resulting solution was extracted with ethyl acetate (3 x 15 mL). The pH of the organic layer was adjusted to 8 to 9 with aqueous potassium carbonate. The combined organic layers were concentrated in vacuo, and the residue was purified by MPLC (water:acetonitrile = 1:1) to afford intermediate 3 as a white solid (48 mg, 22% yield).
[0142] 1 H NMR(400MHz,DMSO-d6)δ12.46(s,1H),8.81(s,2H),7.90(s,1H),6.28(dd,1H),6.11(s,1 H),5.01(s,2H),4.41(d,2H),4.32(t,2H),4.16(t,3H),3.55–3.45(m,2H),1.15(d,3H). LC-MS m / z(ESI)=373.1[M+1].
[0143] Example 1 Preparation of Compound ①
[0144] (S)-4-(Trifluoromethyl)-5-((1-((5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)pyridazin-3(2H)-one (Compound ①)
[0145] (S)-4-(trifluoromethyl)-5-((1-((5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-yl)methoxy)propan-2-yl)amino)pyridazin-3(2H)-one
[0146] Intermediate 3 (48 mg, 0.13 mmol, 1.0 equiv) and 2-chloro-5-trifluoromethylpyrimidine (24 mg, 0.13 mmol, 1.0 equiv) were weighed into a 10 mL reaction vial and dissolved in N,N-dimethylformamide (4.0 mL). N,N-Diisopropylethylamine (0.086 mL, 0.52 mmol, 4 equiv) was added to the mixture, and the reaction was stirred at 90°C for 1 h. After completion of the reaction, the reaction mixture was concentrated in vacuo. The residue was purified by MPLC (water:acetonitrile = 1:1) to afford compound ① as a white solid (40 mg, 59% yield).
[0147] 1 H NMR (400MHz, DMSO-d6): δ12.46(s,1H),8.81(s,2H),7.90(s,1H),6.28(dd,1H),6.11(s, 1H),5.01(s,2H),4.41(d,2H),4.32(t,2H),4.16(t,3H),3.55–3.45(m,2H),1.15(d,3H).
[0148] LCMS m / z=519.40 [M+1].
[0149] Example 2 Preparation of Compound ①A Crystal Form
[0150] Method 1:
[0151] Compound ① (7.8 g) was dissolved in acetonitrile (16 mL) at room temperature, and water (24 mL) was added. The mixture was stirred at room temperature for 4 h to allow crystallization. The filter cake was vacuum-dried at 55°C to obtain Form A.
[0152] Method 2:
[0153] Under nitrogen protection, the crude product of compound ① (5.20 g) was added to acetonitrile (16.50 g), heated to 60-65 ° C and dissolved for 0.5 h; then water (52.43 g) and n-propanol (8.40 g) were added in sequence, heated to 65±5 ° C and dissolved for 0.5 h, cooled to 30±5 ° C and continued to stir for 11 h, allowed to stand for 16 h to crystallize, maintained at 25±5 ° C and continued to crystallize for 6 h, filtered, washed with water (6.09 g), and dried at 55±5 ° C for 16 h to obtain Form A.
[0154] X-ray powder diffraction analysis:
[0155] Form A of compound ① was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Form A are shown in Table 1.
[0156] Table 1 X-ray powder diffraction data of Form A
[0157] The X-ray powder diffraction pattern of compound ①A crystal form is shown in Figure 1.
[0158] TGA and DSC analysis:
[0159] Compound ①'s Form A was subjected to thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). TGA and DSC data were acquired on a Mettler Thermogravimetric Analyzer (Mettler TGA / DSC 3+) and a Mettler Differential Scanning Calorimeter (Mettler DSC 3), respectively. Table 2 lists the TGA and DSC test parameters. The test results are shown in Figures 10 and 11, respectively. The TGA spectrum shows a weight loss of 0.1737% upon heating to 105°C; the DSC spectrum shows an endothermic peak at 139.02°C.
[0160] Table 2 TGA and DSC test parameters
[0161] Example 3 Preparation of Compound ①B Crystal Form
[0162] Compound ① (10 g) prepared in reverse order was dissolved in n-hexane (100 mL), slurried at room temperature for 2 h, filtered, and the solid was dried in vacuo at 55° C. to obtain Form B.
[0163] X-ray powder diffraction analysis:
[0164] Form B of compound ① was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Form B are shown in Table 3.
[0165] Table 3 X-ray powder diffraction data of Form B
[0166] The X-ray powder diffraction pattern of compound ①B crystal form is shown in Figure 2.
[0167] Example 4 Preparation of Compound ①C Crystal Form
[0168] Compound ① (5.1 g) was dissolved in IPAc (isopropyl acetate) (5 mL) at room temperature. The IPAc solution of compound ① was slowly added dropwise to n-hexane (120 mL) while maintaining room temperature. After the addition, the mixture was heated to 60°C and stirred to dissolve. The heating was then turned off and the mixture was naturally cooled to room temperature to precipitate a white flocculent solid. The solid was filtered and the filter cake was vacuum dried at 55°C to obtain Form C.
[0169] X-ray powder diffraction analysis:
[0170] Form C of compound ① was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Form C are shown in Table 4.
[0171] Table 4 X-ray powder diffraction data of compound ①C crystal form
[0172] The X-ray powder diffraction pattern of compound ①C crystal form is shown in Figure 3.
[0173] Example 5 Preparation of Compound ① Crystalline Form D
[0174] The crude product was prepared by reverse reaction of acetonitrile and water, concentrated, extracted with ethyl acetate, concentrated again, and dried in vacuo at 55°C to obtain an off-white solid compound ① (34 g), which was identified as Form D by XRD.
[0175] X-ray powder diffraction analysis:
[0176] Compound ① Form D was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Compound ① Form D are shown in Table 5.
[0177] Table 5 X-ray powder diffraction data of compound ① crystal form D
[0178] The X-ray powder diffraction pattern of compound ① crystal form D is shown in Figure 4.
[0179] Example 6 Preparation of Compound ①E Crystal Form
[0180] Compound ① (2.0 g) was placed in a reaction flask, ethyl acetate (4 mL) was added at room temperature, and the temperature was raised to 60°C and stirred to dissolve. N-hexane (6 mL) was added while maintaining the internal temperature at 60°C and stirring was continued for 2 h. A large amount of white flocs appeared, which was filtered and the filter cake was dried in vacuo at 55°C to obtain Form E.
[0181] X-ray powder diffraction analysis:
[0182] Form E of compound ① was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Form E are shown in Table 6.
[0183] Table 6 X-ray powder diffraction data of Form E
[0184] The X-ray powder diffraction pattern of compound ① crystal form E is shown in Figure 5.
[0185] Example 7 Preparation of Compound ①F Crystal Form
[0186] Weigh compound ① (500 mg) into a 50 mL reaction flask and add 2 mL of n-propanol. Heat to reflux to dissolve. Add 2 mL of n-heptane dropwise until the solution becomes clear again. Cool to room temperature and crystallize for 30 minutes. Filter with suction, and dry the filter cake in vacuo at 55°C for 9 hours to obtain Form F (420 mg).
[0187] X-ray powder diffraction analysis:
[0188] Form F of compound ① was measured using an X-ray diffractometer (Bruker D8 advance, graphite monochromated Cu Kα radiation (λ = 1.54) at room temperature. Method parameters: current voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scan range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data of Form F are shown in Table 7.
[0189] Table 7 X-ray powder diffraction data of Form F
[0190] The X-ray powder diffraction pattern of the compound ①F crystal form is shown in Figure 6.
[0191] TGA and DSC analysis:
[0192] Using the testing conditions for Form A of Compound ①, Form F of Compound ① was subjected to thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC), respectively. The test results are shown in Figures 12 and 13, respectively. The TGA spectrum shows a weight increase of 0.697% upon heating to 105°C; the DSC spectrum shows an endothermic peak value of 126.78°C.
[0193] Example 8 Preparation of Compound ①G Crystal Form
[0194] Compound ① (500 mg) was placed in a 50 mL reaction flask and 2 mL of ethanol was added. The temperature was raised to reflux, and after the solution became clear, 2 mL of n-heptane was added dropwise. After the solution became clear again, the temperature was lowered to room temperature and stirred for 60 minutes to crystallize. The mixture was filtered and the filter cake was vacuum dried at 55°C for 9 hours to obtain 350 mg of a white solid (Compound ① G crystal form).
[0195] X-ray powder diffraction analysis:
[0196] Form G of compound ① was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Form G are shown in Table 8.
[0197] Table 8 X-ray powder diffraction data of Form G
[0198] The X-ray powder diffraction pattern of compound ①G crystal form is shown in Figure 7.
[0199] Example 9 Preparation of Compound ①H Crystal Form
[0200] The crude product of compound ① (2.2 kg) was placed in a reactor, acetonitrile (4.1 kg) was added and stirred to dissolve at room temperature, and then water (7.8 kg) was added and stirred for crystallization for 20 h. 5 L of acetonitrile / H2O mixed solvent (mixed solvent ratio: acetonitrile 4.1 kg + H2O 7.8 kg) was added, and the mixture was stirred for 1 h before centrifugation. The filter cake was vacuum dried at 55°C to obtain compound ①H crystalline form (1.54 kg).
[0201] X-ray powder diffraction analysis:
[0202] Form H of compound ① was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Form H are shown in Table 9.
[0203] Table 9 X-ray powder diffraction data of Form H
[0204] The X-ray powder diffraction pattern of compound ①H crystal form is shown in Figure 8.
[0205] TGA and DSC analysis:
[0206] Using the testing conditions for Form A of Compound ①, Form H of Compound ① was subjected to thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC), respectively. The test results are shown in Figures 14 and 15, respectively. The TGA spectrum shows a weight loss of 0.6674% upon heating to 101.42°C; the DSC spectrum shows an endothermic peak value of 130.05°C.
[0207] Example 10 Preparation of Compound ①I Crystal Form
[0208] The crude product of compound ① (60 g) was placed in a reaction flask, acetonitrile (120 mL) was added and stirred to dissolve at room temperature, water (180 mL) was added and stirred to crystallize for 3 h, acetonitrile (120 mL) / H2O (180 mL) mixed solvent was added, and crystallization was continued for 2 h. The mixture was filtered and the filter cake was vacuum dried at 55°C to obtain Form I (40.5 g).
[0209] X-ray powder diffraction analysis:
[0210] Form I of compound ① was analyzed using an X-ray diffractometer (Bruker D8 advance) at room temperature using graphite monochromated Cu Kα radiation (λ = 1.54). Method parameters included: current and voltage -40 mA, 40 kV; step size: 0.02°; scan rate: 0.2 sec / step; scanning range: 3°-40° 2θ. A powder diffraction pattern was obtained and the data were analyzed. The X-ray powder diffraction data for Form I are shown in Table 10.
[0211] Table 10 X-ray powder diffraction data of Form I
[0212] The X-ray powder diffraction pattern of compound ①I crystal form is shown in Figure 9.
[0213] Biological Examples
[0214] 1. In vivo pharmacokinetic studies
[0215] Appropriate amounts of compound were weighed and prepared into a 1 mg / mL suspension in 5% DMSO + 30% HP-β-CD. Male ICR mice were fasted overnight and then gavage administered. Blood was collected from the jugular venous plexus at time points: 0, 5 minutes, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours. Plasma was anticoagulated with EDTA-K2, and centrifuged for determination of unchanged drug concentration by LC / MS / MS.
[0216] The results showed that compound ①'s crystal forms A, B, C, D, E, F, G, H and I all had good pharmacokinetic properties.
[0217] 2. Stability Study
[0218] 2.1 Influencing factor test
[0219] 2.1.1 Lighting test
[0220] Weigh an appropriate amount of compound into a suitable white, transparent, open container (e.g., weighing bottle or Petri dish). Place in a light-sensitive drug stability test chamber at an illumination of 4500 lx ± 500 lx. Samples should be collected for testing 5, 10, and 30 days after placement.
[0221] 2.1.2 High temperature test
[0222] Weigh an appropriate amount of compound into a suitable open container (such as a weighing bottle or petri dish) and place it in an electric blast drying oven at 60°C. Take samples for testing 5, 10, and 30 days after placement.
[0223] 2.1.3 High humidity test
[0224] Weigh an appropriate amount of compound into a suitable open container (e.g., a weighing bottle or Petri dish). Place in a desiccator containing a saturated KNO3 solution at 25°C ± 2°C and relative humidity of 92.5% and 72.5%, respectively. Samples should be collected and tested 5, 10, and 30 days after placement.
[0225] 2.2 Accelerated test
[0226] An appropriate amount of compound was packaged with inner packaging (pharmaceutical low-density polyethylene film, bag) and outer packaging (polyester / aluminum / polyethylene pharmaceutical composite film, bag), and then tested at a temperature of 40°C ± 2°C and a relative humidity of 75% ± 5%.
[0227] 2.3 Intermediate Conditions
[0228] An appropriate amount of compound was packaged with inner packaging (pharmaceutical low-density polyethylene film, bag) and outer packaging (polyester / aluminum / polyethylene pharmaceutical composite film, bag), and then tested at a temperature of 30°C ± 2°C and a relative humidity of 65% ± 5%.
[0229] 2.4 Long-term trials
[0230] An appropriate amount of compound was packaged with inner packaging (pharmaceutical low-density polyethylene film, bag) and outer packaging (polyester / aluminum / polyethylene pharmaceutical composite film, bag), and then tested at a temperature of 25°C ± 2°C and a relative humidity of 60% ± 5%.
[0231] The results show that compound ①'s crystal forms A, B, C, D, E, F, G, H and I all have good physical and chemical stability.
[0232] The specification of the present invention describes the specific implementation scheme in detail. Those skilled in the art should recognize that the above implementation scheme is exemplary and cannot be understood as limiting the present invention. For those skilled in the art, without departing from the principles of the present invention, by making several improvements and modifications to the present invention, the technical solutions obtained by these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. Crystals of the compound represented by formula ①:
2. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form A has characteristic diffraction peaks at the following 2θ positions: 10.389°±0.3°, 11.917°±0.3°, 12.912°±0.3°, 13.385°±0.3°, 14.054°±0.3°, 15.316°±0.3°, and 16.636°±0.3°.
3. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form A has characteristic diffraction peaks at the following 2θ positions: 6.716°±0.3°, 10.043°±0.3°, 10.389°±0.3°, 11.917°±0.3°, 12.912°±0.3°, 13.385°±0.3°, 14.054°±0.3°, 15.316°±0.3°, 16.636°±0.3°, 18.003°±0.3°, 20.014°±0.3°, 20.794°±0.3°, and 23.855°±0.3°.
4. The crystal according to claim 2 or 3, characterized in that The X-ray powder diffraction pattern of Form A is basically shown in Figure 1.
5. The crystal according to any one of claims 2 to 4, characterized in that The TGA curve of crystal form A is basically shown in Figure 10.
6. The crystal according to any one of claims 2 to 4, characterized in that The DSC curve of Form A is basically shown in FIG11 .
7. A method for preparing the crystal form A according to any one of claims 2 to 6, characterized in that: The compound represented by formula ① is crystallized in a solvent (①-A) to obtain crystal form A; the solvent (①-A) is selected from any one of acetonitrile, ethanol, n-propanol, acetone and water, or a mixed solvent of any several of them in any proportion.
8. The preparation method according to claim 7, characterized in that The compound represented by formula ① or its crude product is added to a solvent (①-A-1), heated to dissolve, and then a solvent (①-A-2) and a solvent (①-A-3) are added, heated to dissolve, cooled and stirred continuously, and allowed to stand for crystallization to obtain Form A; the solvent (①-A-1), the solvent (①-A-2), and the solvent (①-A-3) are selected from any one of acetonitrile, ethanol, n-propanol, acetone, and water.
9. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form B has characteristic diffraction peaks at the following 2θ positions: 6.498°±0.3°, 13.326°±0.3°, 21.229°±0.3°, 21.426°±0.3°, and 22.195°±0.3°.
10. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form B has characteristic diffraction peaks at the following 2θ positions: 6.498°±0.3°, 9.657°±0.3°, 11.420°±0.3°, 13.027°±0.3°, 13.326°±0.3°, 15.882°±0.3°, 19.075°±0.3°, 19.315°±0.3°, 20.669°±0.3°, 21.229°±0.3°, 21.426°±0.3°, 22.195°±0.3°, 23.118°±0.3°, and 23.362°±0.3°.
11. The crystal according to claim 9 or 10, characterized in that The X-ray powder diffraction pattern of Form B is basically shown in Figure 2.
12. A method for preparing the crystal form B according to any one of claims 9 to 11, characterized in that: The compound represented by formula ① is slurried in a solvent (①-B) to obtain crystal form B; the solvent (①-B) is selected from n-hexane.
13. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form C has characteristic diffraction peaks at the following 2θ positions: 19.066°±0.3°, 20.300°±0.3°, 20.978°±0.3°, and 21.616°±0.3°.
14. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of form C has characteristic diffraction peaks at the following 2θ positions: 6.790°±0.3°, 9.917°±0.3°, 11.533°±0.3°, 12.600°±0.3°, 13.556°±0.3°, 13.793°±0.3°, 14.275°±0.3°, 15.008°±0.3°, 16.452°±0.3°, 17.877°±0.3°, 19.066°±0.3°, 19.774°±0.3°, 20.300°±0.3°, 20.978°±0.3°, 21.616°±0.3°, 22.585°±0.3°, and 23.407°±0.3°.
15. The crystal according to claim 13 or 14, characterized in that The X-ray powder diffraction pattern of Form C is basically shown in FIG3 .
16. A method for preparing the crystal form C according to any one of claims 13 to 15, characterized in that: The compound represented by formula ① is crystallized in a solvent (①-C) to obtain crystal form C; the solvent (①-C) is selected from isopropyl acetate, n-hexane or a mixed solvent of isopropyl acetate and n-hexane.
17. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form D has characteristic diffraction peaks at the following 2θ positions: 6.646°±0.3° and 13.175°±0.3°.
18. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form D has characteristic diffraction peaks at the following 2θ positions: 6.646°±0.3°, 13.175°±0.3°, 13.489°±0.3°, 16.450°±0.3°, 20.950°±0.3°, 21.585°±0.3°, 22.369°±0.3°, 23.036°±0.3°, and 23.281°±0.3°.
19. The crystal according to claim 17 or 18, characterized in that The X-ray powder diffraction pattern of Form D is basically shown in FIG4 .
20. A method for preparing the crystal form D according to any one of claims 17 to 19, characterized in that: The compound represented by formula ① is extracted with solvent (①-D), concentrated and vacuum-dried to obtain crystal form D; the solvent (①-D) Selected from ethyl acetate.
21. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of crystal form E has characteristic diffraction peaks at the following 2θ positions: 18.227°±0.3°, 19.954°±0.3°, and 22.449°±0.3°.
22. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of Form E has characteristic diffraction peaks at the following 2θ positions: 8.129°±0.3°, 11.118°±0.3°, 11.360°±0.3°, 11.749°±0.3°, 13.482°±0.3°, 14.730°±0.3°, 18.227°±0.3°, 19.954°±0.3°, 20.712°±0.3°, 21.092°±0.3°, 22.449°±0.3°, 22.813°±0.3°, 24.399°±0.3°, 24.560°±0.3°, 25.923°±0.3°, 26.429°±0.3°, 27.060°±0.3°, 27.446°±0.3°.
23. The crystal according to claim 21 or 22, characterized in that The X-ray powder diffraction pattern of Form E is basically shown in FIG5 .
24. A method for preparing the E crystal form according to any one of claims 21 to 23, characterized in that: The compound represented by formula ① is crystallized in a solvent (①-E) to obtain crystal form E; the solvent (①-E) is selected from ethyl acetate, n-hexane or a mixed solvent of ethyl acetate and n-hexane.
25. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form F has characteristic diffraction peaks at the following 2θ positions: 6.717°±0.3° and 13.484°±0.3°.
26. The crystal according to claim 1, characterized in that The X-ray powder diffraction pattern of crystal form F has characteristic diffraction peaks at the following 2θ positions: 6.717°±0.3°, 9.812°±0.3°, 11.426°±0.3°, 12.501°±0.3°, 13.484°±0.3°, 14.915°±0.3°, 16.374°±0.3°, 16.884°±0.3°, 17.828°±0.3°, 18.975°±0.3°, 20.241°±0.3°, 20.902°±0.3°, 21.593°±0.3°, 22.506°±0.3°, 22.918°±0.3°, and 23.412°±0.3°.
27. The crystal according to claim 25 or 26, characterized in that The X-ray powder diffraction pattern of Form F is basically shown in FIG6 .
28. The crystal according to any one of claims 25 to 27, characterized in that The TGA curve of Form F is basically shown in FIG12 .
29. The crystal according to any one of claims 25 to 27, characterized in that The DSC curve of Form F is basically shown in FIG13 .
30. A method for preparing the F crystal form according to any one of claims 25 to 29, characterized in that: The compound represented by formula ① is crystallized in a solvent (①-F) to obtain crystal form F; the solvent (①-F) is selected from n-propanol, n-heptane or a mixed solvent of n-propanol and n-heptane.
31. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of crystal form G has characteristic diffraction peaks at the following 2θ positions: 6.743°±0.3° and 13.503°±0.3°.
32. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of crystal form G has characteristic diffraction peaks at the following 2θ positions: 6.743°±0.3°, 13.503°±0.3°, 16.901°±0.3°, 18.996°±0.3°, 20.260°±0.3°, 20.920°±0.3°, and 21.604±0.3°.
33. The crystal according to claim 31 or 32, characterized in that The X-ray powder diffraction pattern of Form G is basically shown in FIG7 .
34. A method for preparing the G crystal form according to any one of claims 31 to 33, characterized in that: The compound represented by formula ① is crystallized in a solvent (①-G) to obtain crystal form G; the solvent (①-G) is selected from ethanol, n-heptane or a mixed solvent of ethanol and n-heptane.
35. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of the H crystal form has characteristic diffraction peaks at the following 2θ positions: 12.366°±0.3°, 13.115°±0.3°, 14.359°±0.3°, 15.617°±0.3°, and 16.909°±0.3°.
36. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of the H crystal form has characteristic diffraction peaks at the following 2θ positions: 6.514°±0.3°, 10.074°±0.3°, 10.684°±0.3°, 12.366°±0.3°, 13.115°±0.3°, 14.359°±0.3°, 15.617°±0.3°, 16.909°±0.3°, 19.839°±0.3°, 20.092°±0.3°, 20.687°±0.3°, and 22.919°±0.3°.
37. The crystal according to claim 35 or 36, characterized in that The X-ray powder diffraction pattern of Form H is basically shown in FIG8 .
38. The crystal according to any one of claims 35 to 37, characterized in that The TGA curve of the H crystal form is basically shown in Figure 14.
39. The crystal according to any one of claims 35 to 37, characterized in that The DSC curve of Form H is basically shown in FIG15 .
40. A method for preparing the H crystal form according to any one of claims 35 to 39, characterized in that: The compound represented by formula ① is crystallized in a solvent (①-H) to obtain the H crystal form; the solvent (①-H) is selected from any one of acetonitrile, ethanol, n-propanol, acetone and water, or a mixed solvent of any several of them in any proportion.
41. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of Form I has characteristic diffraction peaks at the following 2θ positions: 4.968°±0.3°, 19.770°±0.3°, and 21.752°±0.3°.
42. The crystal according to claim 1, wherein The X-ray powder diffraction pattern of Form I has characteristic diffraction peaks at the following 2θ positions: 4.968°±0.3°, 8.863°±0.3°, 12.739°±0.3°, 13.896°±0.3°, 14.848°±0.3°, 18.840°±0.3°, 19.179°±0.3°, 19.770°±0.3°, 21.155°±0.3°, 21.752°±0.3°, and 24.053°±0.3°.
43. The crystal according to claim 41 or 42, characterized in that The X-ray powder diffraction pattern of Form I is basically shown in Figure 8.
44. A method for preparing the crystal form I according to any one of claims 41 to 43, characterized in that: The compound represented by formula ① is crystallized in a solvent (①-I) to obtain Form I; the solvent (①-I) is selected from acetonitrile, water or a mixed solvent of acetonitrile and water.
45. A pharmaceutical composition comprising a therapeutically effective amount of the crystal according to any one of claims 1 to 44, and a pharmaceutically acceptable carrier or excipient.
46. Use of the crystal according to any one of claims 1 to 44 or the pharmaceutical composition according to claim 45 in the preparation of a medicament for treating and / or preventing cancer.
